Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Early Phase 1
1(20.0%)
Phase 3
1(20.0%)
5Total
Phase 1(3)
Early Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06732531Phase 1Recruiting

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

Role: lead

NCT06427681Early Phase 1Not Yet Recruiting

An Relative Bioavailability Study of BH006 for Injection in Healthy Subjects

Role: lead

NCT06232863Phase 1Unknown

A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer

Role: lead

NCT06231277Phase 1Completed

Phase I Clinical Trial of BH002 in Patients With Advanced Solid Tumors

Role: lead

NCT04889599Phase 3Completed

A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours

Role: lead

All 5 trials loaded